Market research
SPARC.NSE Sun Pharma Advanced Research Company Limited
NSE INR Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 58B
- P/E ratio
- 3.65
- Analyst target
- 2000
- Dividend yield
- Not available
- Beta
- 0.65
Profile
Instrument facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE232I01014
- Market cap
- 58B
- P/E ratio
- 3.65
- Analyst target
- 2000
- Dividend yield
- Not available
- Beta
- 0.65
About
About Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited engages in the research and development of pharmaceutical products in India and internationally. It develops Sezaby, a benzyl alcohol and propylene glycol free formulation of phenobarbital sodium injection for the treatment of neonatal seizures; SPARC-121, a novel topical agent for the treatment of Alopecia Areata; and SPARC-122, an anti-MUC1 ADC for treatment of multiple cancer indications. The company is also involved in the development of PDP-716 for treatment of open-angle glaucoma. Sun Pharma Advanced Research Company Limited was incorporated in 2006 and is based in Mumbai, India.
Research context
Sun Pharma Advanced Research Company Limited appears in PyInvesting’s India Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the SPARC.NSE discussion.
5 years, 6 months ago
Sun Pharma Advanced Research Company Limited is currently in a long term uptrend where the price is trading 31.6% above its 200 day moving average.
From a valuation standpoint, the stock is 259.2% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 17.2.
Sun Pharma Advanced Research Company Limited's total revenue rose by 11.3% to $218M since the same quarter in the previous year.
Its net income has dropped by 21.8% to $-676M since the same quarter in the previous year.
Finally, its free cash flow grew by 89.2% to $-157M since the same quarter in the previous year.
Based on the above factors, Sun Pharma Advanced Research Company Limited gets an overall score of 3/5.